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Microinvasive carcinoma of the cervix
Milica ﬁivaljevi￿, Tamara Vujkov, Dejan NinŁi￿, Aljo„a Mandi￿, Dragan ﬁiki￿, Katarina
Mastilovi￿
ABSTRACT
BACKGROUND: Superficially invasive neoplasias of the uterine cervix are a matter of controversy in
terms of their definition, prognostic factors and selection of treatment to minimize the risk of recur-
rences.
METHODS: Forty-three women with invasive cervical carcinoma, operated from 1993 to 2003, were
postoperatively staged as IA cervical carcinoma. There were 28 patients who were submitted to class III
radical hysterectomy, 9 patients to class II hysterectomy, 2 patients to class I hysterectomy, and 2
patients to abdominal trachelectomy and pelvic lymph node dissection. Mean age of patients was 44
years (range, 27-64 years).
RESULTS: Twenty-three patients (56.1%) were stage with IA1 and 18 (43.9%) with stage IA2 disease
according to the 1995 FIGO classification. Tumor histology revealed squamous cell carcinoma in 38
(92.6%) cases, adenocarcinoma in 2 (4.8%) cases and glassy cell carcinoma in 1 (2.4%). The average
number of examined lymph nodes was 17.4 (2-53). Lymphovascular space invasion was identified in 3
patients. None of the 41 patients had metastasis to the pelvic lymph nodes or developed recurrence of
disease.
CONCLUSION: The results suggest that patients with cervical cancer stage IA1 have an extremely low
risk of pelvic lymph node metastasis and an excellent prognosis, so nonradical management that
excludes pelvic lymph node dissection could be as effective as radical surgery in these patients. Stage
IA2 invasive squamous carcinoma of the cervix should be treated with radical hysterectomy with lymph
node dissection considering the presence of risk factors. The treatment should be individualized and
based on an exhaustive pathological evaluation of an adequate cone biopsy specimen.
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INTRODUCTION 
C
ervical carcinoma is the commonest gynecological cancer and is in the second place
among women with malignant diseases in Vojvodina (9.4%). Despite the availability of
Pap smear screening, almost 324 women in Vojvodina will be diagnosed with invasive cer-
vical cancer each year and nearly 146 women will die of cervical cancer each year (1). 
Microinvasive carcinoma of the cervix is an invasive lesion identified only microscopically.
All greater tumors even with superficial invasion are stage IB cancers according to 1995
FIGO classification. Mean age of patients is 40 years. The disease is asymptomatic, usual-
ly found during investigation for abnormal Pap smear. Cervix often appears normal on rou-
tine pelvic exam. The diagnosis can be made only by means of a thoroughly examined
conization specimen. With recurrence rates in these two substages, which are no more than
1% to 2%, it has excellent prognosis. Survival of stage IA1 can approach 99% and stage
IA2 can approach 97%-98% (2).
PATIENTS AND METHODS
This retrospective study was performed in the Institute of Oncology in Sremska Kamenica
between 1993 and 2003. We analyzed the data from patients’ histories of 41 women with
invasive cervical carcinoma, who underwent to radical hysterectomy and lymphadenecto-
my and were postoperatively staged as IA cervical carcinoma. Histopatholgical examination
of cervical biopsy and/or cervical curettement revealed invasive cervical carcinoma, preop-
eratively staged as IB1. There were 28 patients who were submitted to class III radical hys-
terectomy, 9 patients to class II hysterectomy, 2 patients to class I hysterectomy, and 2
patients to abdominal trachelectomy and pelvic lymph node dissection. Mean age of
patients was 44 years (range, 27-64 years).
RESULTS
A total of 41 patients were followed from 1 to 10 years with a median follow-up interval of
4.6 years. There were 23 (56.1%) patients with early stromal invasion (IA1) and 18 (43.9%)
with microinvasive carcinoma (IA2) according to FIGO criteria (1995). Tumor histology
revealed squamous cell carcinoma in 38 (92.6%) cases, adenocarcinoma in 2 (4.8%)
cases, and glassy cell carcinoma in 1 (2.4%). 
Seven patients were submitted to conization, but for all of them treatment was completed
with radical hysterectomy and pelvic lymph node dissection due to diagnosis of stage IA2
invasive cervical carcinoma and/or lymphovascular space invasion. Other 34 patients were
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primary radically operated.
The average number of lymph nodes examined was 17.4 (2-53). None of the 41 patients
had metastasis to the pelvic lymph nodes. Lymphovascular space invasion was identified
in 3 patients. None of 41 patients developed recurrence or died from recurrent disease.
DISCUSSION
The diagnosis and management of microinvasive carcinoma of the cervix are one of the
most controversial areas in gynecologic oncology. The staging criteria have changed sev-
eral times during the past decades. The recommended therapy has also changed, going
from radical surgery with any invasion to being more conservative with various depths of
invasion.
In 1973, the Society of Gynecologic Oncologists (SGO) defined the microinvasive lesion as
one in which neoplastic epithelium invades the stroma in one or more places to the depth
of 3 mm or less below the base of the epithelium and in which lymphatic or vascular
involvement is not demonstrated. This definition was used as a guide for therapy by many
physicians mostly in the United States (2).
In 1979, The Japanese Society of Obstetrics and Gynecology adopted the SGO definition
except patients with confluent patterns of invasion who were excluded and were considered
to belong to stage IB1.
In 1995 The Cancer Committee of the International Federation of Obstetrics and Gynecology
(FIGO) subdivided stage I cervical cancer into stage IA1, IA2, IB1, and IB2 (Table 1). Stage
IA1 carcinoma of the cervix is a lesion which invades the cervical stroma to a depth of 3.0
mm or less bellow the base of the epithelium, and no more than 7.0 mm wide. In stage IA2
invasion is limited to measured stromal invasion with maximum depth of 5 mm and not
wider than 7 mm. FIGO classification is made for comparison purposes and not as the
guide for therapy (3).
Lymphatic vascular space involvement would not exclude a patient from FIGO definition of
stage IA cervical carcinoma. However, there are many reports about significant prognostic
factors that predict lymph node metastases and survival. Depth of invasion and lymphatic
vascular space invasion are the most important prognostic parameters for lymph node
involvement and the risk of recurrence (4) (Table 2). Incidence of lymphatic vascular space
invasion in stage IA1 and IA2 is 5% and 25% (5).
Patients with cervical cancer stage IA1 have an extremely low risk of pelvic lymph node
metastases (less than 0.5%) (6). In a group of 180 patients Copeland et al. demonstrated
a 0.3% risk of pelvic node metastases in patients without lymphovascular space involve-
ment whose lesions invaded 3 mm or less. The presence of lymphovascular space involve-
ment increased the risk of nodal metastases to 2.6% and of recurrence to 4% (7). 
In 82 patients with 3 mm or less depth of invasion Takeshima found the incidence of lymph
node metastasis in 1.2%. The incidence of lymph node metastasis was 3.4% in patients
with 3 to 5 mm depth of invasion. None of the patients in this series had metastasis to the
parametrial tissues (8).
Patients with carcinoma where depth of invasion extends to 5 mm have increased risk of
lymphovascular space involvement and metastatic disease. The pelvic node metastasis
rates lie between 3 and 5% (2). In Burghardt’s review of 409 patients with microinvasive
carcinoma 7 (1.7%) patients developed fatal recurrences (9).
So, the therapy of microinvasive cervical cancer (stage IA1 and IA2) depends on the pres-
ence of significant prognostic factors and must be individualized. It depends on depth of
invasion, superficial spread of lesion, lymphovascular space infiltration, poor differentiation,
confluent pattern of invasion, lymph node involvement and positive cone margins (10).
Exact work-up of the cone is the basis for successful treatment.
Patients with cervical cancer stage IA1 have an extremely low risk of pelvic lymph node
metastases and they can be treated safely with cervical conization, or simple hysterectomy
(11). Every histologic criteria of this definition must be met and all conization margins must
be free of dysplasia or invasive disease. Patients must be reliable so that they can be fol-
lowed closely with periodic Pap smears to detect recurrent cervical neoplasia. 
Patients with FIGO stage IA1 cervical cancer and lymph vascular space invasion or positive
cone margins should be treated by class II radical hysterectomy and pelvic lymph node dis-
section.
Patients with stage IA2 cervical cancer have a significant risk for lymph nodal metastases,
and should be treated with radical surgery - class III radical hysterectomy with pelvic node
dissection. Considering the risk of recurrence is not very high, lower than 5%, some other
risk factors of recurrence have to be taken into account in modifying management, like lym-
phovascular space involvement, confluent growth pattern and poor differentiation.  
Young patients, who desire to preserve childbearing function, can be treated with radical
trachelectomy and pelvic lymphadenectomy.
CONCLUSION
Superficially invasive neoplasias of the uterine cervix are a matter of controversy in terms
of their definition, prognostic factors and selection of treatment to minimize the risk of
recurrences. With increased experience, more conservative therapy was found to be just as
efficacious as radical therapy. Conservative therapy for stage IA2 carcinoma of the cervix
does not seem unreasonable. These questions will be resolved in the future as more data
is accumulated.
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ABSTRACT
BACKGROUND: The serious nature of potentially malignant oral lesions (PMOL) demands that the final
diagnosis be made on both clinical and histopathologic grounds. The aim of the present study was to
determine the correlation between clinical and histopathologic diagnoses of PMOL using a discrepancy
index (DI).
METHODS: Fifty-one patients with PMOL were examined clinically, and a biopsy was taken from each
one. The results of histopathologic diagnosis were compared with the clinical diagnosis. We established
that the histopathologic diagnosis was incompatible when the clinical diagnosis was not confirmed. On
the basis of the incompatible diagnosis, we calculated a discrepancy index between the clinical and
histopathologic diagnosis.
RESULTS: Clinically, the homogeneous leukoplakia was the most frequent lesion followed by erosive
lichen planus and reticular lichen planus. No cases of erythroplakia were observed. Lesions were most
frequently seen at the buccal mucosa, followed by the gingiva (alveolar mucosa) and tongue. The
histopathologic diagnosis showed that the majority of the lesions were benign keratoses followed by
lichen planus. Three cases of epithelial dysplasia were mild. The DI between clinical and histopatholog-
ic diagnosis was 17.6 %. The higher DI was found in erosive lichen planus.
CONCLUSION: The obtained findings show that in 90% of leukoplakias, clinical diagnosis was confirmed
by histopathologic examination. The discrepancy between clinical and histopathologic diagnoses in 17.6
% of cases suggests that all PMOLs should be submitted to histological analysis.
KEY WORDS: Leukoplakia, Oral; Lichen Planus, Oral; Precancerous Conditions; Mouth Disease;
Diagnosis, Oral
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INTRODUCTION 
A
potentially malignant oral lesion (PMOL) has been defined as a morphologically altered
tissue in which cancer is more likely to develop than in its apparently normal counter-
part. Leukoplakia is the most common potentially malignant lesion of the oral mucosa (1).
It has been suggested that widespread multiple leukoplakias may have a higher potential for
developing carcinoma regardless of the grade of epithelial dysplasia (2). Although some
previous studies have shown generally poor agreement among pathologists in the
histopathologic assessment of oral premalignant lesions (3,4), the taking of a biopsy in
leukoplakias should be the standard rule. The problem in such lesions is not so much the
histopathologic evaluation of the presence of epithelial dysplasia as it is the possible inva-
sive nature of the lesion (5).
Oral lichen planus (OLP) is one of the most prevalent oral mucosal lesions with an increased
potential for malignant development (6). Because of the variations in appearance, the diag-
nosis of OLP should not be assessed on the histopathologic picture alone, but should also
be based on distinct clinical criteria. Histopathologically, typical OLP in a substantial per-
centage does not correlate with a typical clinical appearance (7).
The management of PMOL is problematical and is largely dependent on the collection of
both clinical and histopathologic information.
The aim of the present study was to determine the correlation between clinical and
histopathologic diagnoses of PMOL using the discrepancy index.
PATIENTS AND METHODS
The study population comprised 51 patients (31 women and 20 men) aged from 42 to 76
years, who visited the Department of Oral Medicine and Periodontology of the Clinic of
Stomatology in Novi Sad, between January 2002 and December 2003. After the patients
had provided their consent form, all clinical examinations were performed by one of the
authors, with 20-year experience in the diagnostics of oral mucosal lesions. A history was
taken from each patient, and the exact location of all lesions were noted down in a case
report form, which contained a schematic presentation of the dorsal and ventral view of the
mouth, including lips, labial mucosa, gingiva, vestibule, buccal mucosa, floor of mouth,
hard palate, soft palate and tongue. The lesions presented clinically as: (i) homogeneous
leukoplakia; (ii) non-homogeneous leukoplakia; (iii) erythroplakia; (iv) lichen planus, and (v)
actinic cheilitis were determined to be potentially malignant lesions. The clinical diagnosis
was reached according to the criteria described in Table 1. 
Histopathologic examination of all lesions was performed. If the lesions were small, an exci-
sional biopsy was usually performed. For the large lesions, an incisional biopsy was per-
formed and multiple specimens from different areas were taken. The biopsy specimens